# AtriCure, Inc.: financial statements, quarterly ATRC · Nasdaq · CIK 1323885 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/atrc.md) · [Financials](/companies/atrc/financials.md) · [Filings](/companies/atrc/filings.md) · [Insiders](/companies/atrc/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atrc/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [98.3](/filings/0001323885-24-000117.md) | [107 d](/filings/0001323885-26-000007.md) | [109](/filings/0001323885-25-000043.md) | [116](/filings/0001323885-25-000095.md) | [116](/filings/0001323885-25-000103.md) | [124 d](/filings/0001323885-26-000007.md) | [124](/filings/0001323885-26-000023.md) | [136](/filings/0001323885-26-000035.md) | [134](/filings/0001323885-25-000103.md) | [141 d](/filings/0001323885-26-000007.md) | [141](/filings/0001323885-26-000023.md) | [154](/filings/0001323885-26-000035.md) | | Cost of revenue | $m | [24.4](/filings/0001323885-24-000117.md) | [26.7 d](/filings/0001323885-26-000007.md) | [27.6](/filings/0001323885-25-000043.md) | [29.4](/filings/0001323885-25-000095.md) | [29.1](/filings/0001323885-25-000103.md) | [31.7 d](/filings/0001323885-26-000007.md) | [31.0](/filings/0001323885-26-000023.md) | [34.7](/filings/0001323885-26-000035.md) | [32.9](/filings/0001323885-25-000103.md) | [35.2 d](/filings/0001323885-26-000007.md) | [31.9](/filings/0001323885-26-000023.md) | [35.0](/filings/0001323885-26-000035.md) | | Gross profit | $m | [73.9](/filings/0001323885-24-000117.md) | [79.8 d](/filings/0001323885-26-000007.md) | [81.3](/filings/0001323885-25-000043.md) | [86.8](/filings/0001323885-25-000095.md) | [86.8](/filings/0001323885-25-000103.md) | [92.6 d](/filings/0001323885-26-000007.md) | [92.6](/filings/0001323885-26-000023.md) | [101](/filings/0001323885-26-000035.md) | [101](/filings/0001323885-25-000103.md) | [105 d](/filings/0001323885-26-000007.md) | [109](/filings/0001323885-26-000023.md) | [119](/filings/0001323885-26-000035.md) | | Research and development | $m | [20.4](/filings/0001323885-24-000117.md) | [20.8 d](/filings/0001323885-26-000007.md) | [19.8](/filings/0001323885-25-000043.md) | [20.4](/filings/0001323885-25-000095.md) | [21.0](/filings/0001323885-25-000103.md) | [35.0 d](/filings/0001323885-26-000007.md) | [22.5](/filings/0001323885-26-000023.md) | [29.3](/filings/0001323885-26-000035.md) | [22.9](/filings/0001323885-25-000103.md) | [24.5 d](/filings/0001323885-26-000007.md) | [24.2](/filings/0001323885-26-000023.md) | [26.4](/filings/0001323885-26-000035.md) | | Selling, general and administrative | $m | [61.6](/filings/0001323885-24-000117.md) | [67.7 d](/filings/0001323885-26-000007.md) | [72.3](/filings/0001323885-25-000043.md) | [73.6](/filings/0001323885-25-000095.md) | [73.2](/filings/0001323885-25-000103.md) | [72.2 d](/filings/0001323885-26-000007.md) | [76.1](/filings/0001323885-26-000023.md) | [78.4](/filings/0001323885-26-000035.md) | [78.2](/filings/0001323885-25-000103.md) | [78.3 d](/filings/0001323885-26-000007.md) | [84.6](/filings/0001323885-26-000023.md) | [82.6](/filings/0001323885-26-000035.md) | | Operating income | $m | [(8.1)](/filings/0001323885-24-000117.md) | [(8.7) d](/filings/0001323885-26-000007.md) | [(10.9)](/filings/0001323885-25-000043.md) | [(7.2)](/filings/0001323885-25-000095.md) | [(7.4)](/filings/0001323885-25-000103.md) | [(14.5) d](/filings/0001323885-26-000007.md) | [(6.0)](/filings/0001323885-26-000023.md) | [(6.2)](/filings/0001323885-26-000035.md) | [0.2](/filings/0001323885-25-000103.md) | [2.5 d](/filings/0001323885-26-000007.md) | [0.5](/filings/0001323885-26-000023.md) | [9.7](/filings/0001323885-26-000035.md) | | Interest expense | $m | [1.8](/filings/0001323885-23-000110.md) | [1.8 d](/filings/0001323885-24-000016.md) | [1.7](/filings/0001323885-24-000062.md) | [1.6](/filings/0001323885-25-000095.md) | [1.7](/filings/0001323885-25-000103.md) | [1.5 d](/filings/0001323885-26-000007.md) | [1.4](/filings/0001323885-26-000023.md) | [1.5](/filings/0001323885-26-000035.md) | [1.5](/filings/0001323885-25-000103.md) | [1.5 d](/filings/0001323885-26-000007.md) | [1.3](/filings/0001323885-26-000023.md) | [1.3](/filings/0001323885-26-000035.md) | | Income tax | $m | [0.0](/filings/0001323885-24-000117.md) | [0.4 d](/filings/0001323885-26-000007.md) | [0.2](/filings/0001323885-25-000043.md) | [0.3](/filings/0001323885-25-000095.md) | [0.3](/filings/0001323885-25-000103.md) | [0.3 d](/filings/0001323885-26-000007.md) | [0.2](/filings/0001323885-26-000023.md) | [0.3](/filings/0001323885-26-000035.md) | [0.2](/filings/0001323885-25-000103.md) | [0.6 d](/filings/0001323885-26-000007.md) | [0.3](/filings/0001323885-26-000023.md) | [0.5](/filings/0001323885-26-000035.md) | | Net income | $m | [(9.1)](/filings/0001323885-24-000117.md) | [(9.8) d](/filings/0001323885-26-000007.md) | [(13.3)](/filings/0001323885-25-000043.md) | [(8.0)](/filings/0001323885-25-000095.md) | [(7.9)](/filings/0001323885-25-000103.md) | [(15.6) d](/filings/0001323885-26-000007.md) | [(6.7)](/filings/0001323885-26-000023.md) | [(6.2)](/filings/0001323885-26-000035.md) | [(0.3)](/filings/0001323885-25-000103.md) | [1.8 d](/filings/0001323885-26-000007.md) | [0.1](/filings/0001323885-26-000023.md) | [9.0](/filings/0001323885-26-000035.md) | | Diluted EPS | $ per share | [(0.20)](/filings/0001323885-24-000117.md) | not reported | [(0.28)](/filings/0001323885-25-000043.md) | [(0.17)](/filings/0001323885-25-000095.md) | [(0.17)](/filings/0001323885-25-000103.md) | not reported | [(0.14)](/filings/0001323885-26-000023.md) | [(0.13)](/filings/0001323885-26-000035.md) | [(0.01)](/filings/0001323885-25-000103.md) | not reported | [0.00](/filings/0001323885-26-000023.md) | [0.18](/filings/0001323885-26-000035.md) | | Basic EPS | $ per share | [(0.20)](/filings/0001323885-24-000117.md) | not reported | [(0.28)](/filings/0001323885-25-000043.md) | [(0.17)](/filings/0001323885-25-000095.md) | [(0.17)](/filings/0001323885-25-000103.md) | not reported | [(0.14)](/filings/0001323885-26-000023.md) | [(0.13)](/filings/0001323885-26-000035.md) | [(0.01)](/filings/0001323885-25-000103.md) | not reported | [0.00](/filings/0001323885-26-000023.md) | [0.18](/filings/0001323885-26-000035.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [80.6](/filings/0001323885-23-000110.md) | [84.3](/filings/0001323885-25-000009.md) | [65.0](/filings/0001323885-24-000062.md) | [106](/filings/0001323885-24-000106.md) | [130](/filings/0001323885-24-000117.md) | [123](/filings/0001323885-26-000007.md) | [99.9](/filings/0001323885-25-000043.md) | [118](/filings/0001323885-25-000095.md) | [148](/filings/0001323885-25-000103.md) | [167](/filings/0001323885-26-000035.md) | [146](/filings/0001323885-26-000023.md) | [168](/filings/0001323885-26-000035.md) | | Current assets | $m | [253](/filings/0001323885-23-000110.md) | [266](/filings/0001323885-25-000009.md) | [245](/filings/0001323885-24-000062.md) | [253](/filings/0001323885-24-000106.md) | [269](/filings/0001323885-24-000117.md) | [268](/filings/0001323885-26-000007.md) | [251](/filings/0001323885-25-000043.md) | [271](/filings/0001323885-25-000095.md) | [301](/filings/0001323885-25-000103.md) | [323](/filings/0001323885-26-000035.md) | [314](/filings/0001323885-26-000023.md) | [346](/filings/0001323885-26-000035.md) | | Total assets | $m | [600](/filings/0001323885-23-000110.md) | [614](/filings/0001323885-25-000009.md) | [592](/filings/0001323885-24-000062.md) | [597](/filings/0001323885-24-000106.md) | [615](/filings/0001323885-24-000117.md) | [609](/filings/0001323885-26-000007.md) | [592](/filings/0001323885-25-000043.md) | [609](/filings/0001323885-25-000095.md) | [635](/filings/0001323885-25-000103.md) | [654](/filings/0001323885-26-000035.md) | [644](/filings/0001323885-26-000023.md) | [677](/filings/0001323885-26-000035.md) | | Current liabilities | $m | [82.5](/filings/0001323885-23-000110.md) | [74.6](/filings/0001323885-25-000009.md) | [61.3](/filings/0001323885-24-000062.md) | [61.2](/filings/0001323885-24-000106.md) | [74.4](/filings/0001323885-24-000117.md) | [73.4](/filings/0001323885-26-000007.md) | [61.2](/filings/0001323885-25-000043.md) | [68.8](/filings/0001323885-25-000095.md) | [77.8](/filings/0001323885-25-000103.md) | [81.5](/filings/0001323885-26-000035.md) | [73.2](/filings/0001323885-26-000023.md) | [81.9](/filings/0001323885-26-000035.md) | | Total liabilities | $m | [137](/filings/0001323885-23-000110.md) | [148](/filings/0001323885-25-000009.md) | [135](/filings/0001323885-24-000062.md) | [135](/filings/0001323885-24-000106.md) | [150](/filings/0001323885-24-000117.md) | [148](/filings/0001323885-26-000007.md) | [137](/filings/0001323885-25-000043.md) | [144](/filings/0001323885-25-000095.md) | [159](/filings/0001323885-25-000103.md) | [162](/filings/0001323885-26-000035.md) | [152](/filings/0001323885-26-000023.md) | [160](/filings/0001323885-26-000035.md) | | Long-term debt | $m | [42.2](/filings/0001323885-23-000110.md) | [60.6](/filings/0001323885-25-000009.md) | [61.9](/filings/0001323885-24-000062.md) | [61.9](/filings/0001323885-24-000106.md) | [61.9](/filings/0001323885-24-000117.md) | [61.9](/filings/0001323885-26-000007.md) | [61.9](/filings/0001323885-25-000043.md) | [61.9](/filings/0001323885-25-000095.md) | [61.9](/filings/0001323885-25-000103.md) | [61.9](/filings/0001323885-26-000035.md) | [61.0](/filings/0001323885-26-000023.md) | [61.0](/filings/0001323885-26-000035.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [463](/filings/0001323885-24-000117.md) | [466](/filings/0001323885-26-000007.md) | [456](/filings/0001323885-25-000095.md) | [462](/filings/0001323885-25-000103.md) | [465](/filings/0001323885-25-000103.md) | [461](/filings/0001323885-26-000035.md) | [455](/filings/0001323885-26-000035.md) | [464](/filings/0001323885-26-000035.md) | [477](/filings/0001323885-25-000103.md) | [492](/filings/0001323885-26-000035.md) | [492](/filings/0001323885-26-000035.md) | [516](/filings/0001323885-26-000035.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [1.5 d](/filings/0001323885-24-000117.md) | [4.0 d](/filings/0001323885-26-000007.md) | [(21.0)](/filings/0001323885-25-000043.md) | [7.4 d](/filings/0001323885-25-000095.md) | [20.0 d](/filings/0001323885-25-000103.md) | [5.8 d](/filings/0001323885-26-000007.md) | [(11.0)](/filings/0001323885-26-000023.md) | [21.6 d](/filings/0001323885-26-000035.md) | [26.7 d](/filings/0001323885-25-000103.md) | [20.0 d](/filings/0001323885-26-000007.md) | [(4.0)](/filings/0001323885-26-000023.md) | [22.2 d](/filings/0001323885-26-000035.md) | | Capital expenditure | $m | [3.6 d](/filings/0001323885-24-000117.md) | [2.8 d](/filings/0001323885-26-000007.md) | [2.8](/filings/0001323885-25-000043.md) | [2.4 d](/filings/0001323885-25-000095.md) | [3.6 d](/filings/0001323885-25-000103.md) | [2.7 d](/filings/0001323885-26-000007.md) | [2.2](/filings/0001323885-26-000023.md) | [2.7 d](/filings/0001323885-26-000035.md) | [2.6 d](/filings/0001323885-25-000103.md) | [1.6 d](/filings/0001323885-26-000007.md) | [3.9](/filings/0001323885-26-000023.md) | [3.8 d](/filings/0001323885-26-000035.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [45.8](/filings/0001323885-23-000110.md) | [46.1](/filings/0001323885-24-000062.md) | [46.3](/filings/0001323885-24-000106.md) | [46.4](/filings/0001323885-24-000117.md) | [46.7](/filings/0001323885-25-000043.md) | [46.9](/filings/0001323885-25-000095.md) | [47.1](/filings/0001323885-25-000103.md) | [47.4](/filings/0001323885-26-000023.md) | [47.7](/filings/0001323885-26-000035.md) | [47.9](/filings/0001323885-25-000103.md) | [49.0](/filings/0001323885-26-000023.md) | [48.9](/filings/0001323885-26-000035.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 50,866,294 at 2026-07-22, from the cover of the [10-Q filed 2026-07-27](/filings/0001323885-26-000035.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.